BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pallozzi M, Di Tommaso N, Maccauro V, Santopaolo F, Gasbarrini A, Ponziani FR, Pompili M. Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. Cancers 2022;14:4631. [DOI: 10.3390/cancers14194631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Cui Z, Wang J, Chen G, Li D, Cheng B, Lai Y, Wu Z. The upregulation of CLGN in hepatocellular carcinoma is potentially regulated by hsa-miR-194-3p and associated with patient progression. Front Oncol 2022;12:1081510. [PMID: 36698420 DOI: 10.3389/fonc.2022.1081510] [Reference Citation Analysis]
2 Li S, Wu J, Wu J, Fu Y, Zeng Z, Li Y, Li H, Liao W, Yan M. Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study. Front Immunol 2023;14:1109771. [PMID: 36875116 DOI: 10.3389/fimmu.2023.1109771] [Reference Citation Analysis]
3 Ponziani FR, Giannini EG, Lai Q. Machine learning and biomarkers in hepatocellular carcinoma: The future is now. Liver Cancer International 2022;3:111-112. [DOI: 10.1002/lci2.67] [Reference Citation Analysis]